Every 8-K that Olema Pharmaceuticals, Inc. (OLMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OLMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OLMA filings page.
Olema Pharmaceuticals appointed Jason O’Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 11, 2026. He brings more than two decades of finance leadership in biotechnology and pharmaceuticals, including CFO roles at Vir Biotechnology and Caribou Biosciences and senior finance positions at Audentes Therapeutics, Genentech and Roche.
Under his offer letter, O’Byrne will receive a $545,000 annual base salary, a target bonus equal to 45% of base salary, and sign-on bonuses totaling $350,000, subject to service-based repayment obligations. Subject to Board approval, he will receive an option to purchase 650,000 shares of common stock under Olema’s 2022 Inducement Plan, vesting over four years.
If terminated without Cause or if he resigns for Good Reason, including in connection with a Change in Control, he is eligible for severance benefits that may include up to 12 months of salary, target bonus, prorated bonus, equity vesting acceleration, and up to 12 months of COBRA premium reimbursement.
Olema Oncology (Olema Pharmaceuticals, Inc.) reported second quarter 2026 results and key pipeline milestones. Enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant in ER+/HER2- metastatic breast cancer is complete, with top-line data now expected in the first quarter of 2027. Enrollment is advancing in the OPERA-02 Phase 3 combination trial with ribociclib and in multiple Phase 1/2 combination studies. Initial Phase 1 monotherapy data for KAT6 inhibitor OP-3136 showed it was well-tolerated with evidence of anti-tumor activity, and a new collaboration with Bayer will evaluate OP-3136 plus darolutamide in metastatic castration-resistant prostate cancer.
Olema ended June 30, 2026 with $461.1 million in cash, cash equivalents, and marketable securities. Net loss for the quarter was $63.2 million versus $43.8 million a year earlier, driven mainly by higher clinical and corporate spending to support late-stage trials and commercialization planning. GAAP R&D expense was $57.8 million and GAAP G&A was $9.4 million; on a non-GAAP basis, excluding stock-based compensation, R&D was $48.9 million and G&A was $5.4 million.
Olema Pharmaceuticals, Inc. reported the results of its annual stockholder meeting held on June 17, 2026. Stockholders elected four Class III directors—Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport—to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also approved, on an advisory basis, the executive compensation program, with about 68 million votes in favor and relatively few votes against or abstaining. In addition, they strongly ratified the Audit Committee’s selection of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. No other matters were brought to a vote.
Olema Pharmaceuticals has entered a clinical trial collaboration and supply agreement with Bayer to test its investigational KAT6 inhibitor OP-3136 with Bayer’s androgen receptor inhibitor NUBEQA (darolutamide) in metastatic castration-resistant prostate cancer.
The planned Phase 1b/2 study will evaluate safety, tolerability, and preliminary anti-tumor activity of the combination in approximately 36 patients with mCRPC and is expected to start in the second half of 2026. Bayer will supply darolutamide, while Olema will lead the trial.
All clinical data and inventions related to the combination will be jointly owned, and Olema will retain full global commercial and marketing rights to OP-3136. This is the first clinical collaboration for OP-3136 and extends its development beyond breast cancer into prostate cancer.
Olema Pharmaceuticals reported encouraging preliminary Phase 1 data for OP-3136, its oral KAT6 inhibitor, in advanced solid tumors. In 32 heavily pretreated patients across ER+/HER2- breast, metastatic castration-resistant prostate, and metastatic non-small cell lung cancers, doses from 2 mg to 45 mg once daily were evaluated.
OP-3136 was well-tolerated with no dose-limiting toxicities, no grade 4 or 5 treatment-related adverse events, and no discontinuations due to treatment-related events. Among 19 response-evaluable patients, tumor shrinkage occurred in 13, including 3 partial responses, 2 of which were confirmed. Eleven patients remain on treatment, with the longest treatment duration at 62 weeks. OP-3136 showed rapid, sustained reduction of its histone target and predictable, dose-proportional pharmacokinetics, supporting continued monotherapy and combination development.
Olema Oncology reported first quarter 2026 results highlighted by heavy investment in late-stage breast cancer programs and a strong cash position. Cash, cash equivalents, and marketable securities were $505.3 million as of March 31, 2026. Net loss was $53.1 million, compared with $30.4 million a year earlier, reflecting increased spending on clinical development and corporate activities.
GAAP R&D expenses rose to $49.2 million from $30.6 million, while GAAP G&A expenses increased to $8.8 million from $4.2 million, driven in part by higher non-cash stock-based compensation. Non-GAAP R&D and G&A expenses were $42.7 million and $5.2 million, respectively. The company expects top-line data from its pivotal Phase 3 OPERA-01 trial this fall, continues enrollment in the Phase 3 OPERA-02 trial, and plans for an anticipated first commercial launch next year.
Olema Pharmaceuticals, Inc. entered a seven-year lease with KR Oyster Point II, LLC for a new headquarters totaling approximately 38,176 square feet across two floors in South San Francisco. The company plans to relocate its corporate headquarters to this space by December 2026 as existing San Francisco leases expire between December 2026 and January 2027.
The Lease sets total base rent of $12,361,188.00 for Phase I and $6,145,463.76 for Phase II during the initial term, net of rent abatement. Olema must provide a cash security deposit of $427,546.80 and may terminate once at month 60 by paying a $1,716,240.96 fee. The agreement includes a five-year extension option and a right of first offer on additional space, while the landlord funds specified build-out work and can terminate if Olema fails to cure certain breaches.
Olema Oncology has appointed Dr. Prakash Raman as a Class II director, effective April 28, 2026, with his term running until the company’s 2028 annual stockholders’ meeting. The board determined he is an independent director under Nasdaq rules and reported no related-party transactions.
Under Olema’s non-employee director compensation policy, Dr. Raman received a nonstatutory stock option to purchase 24,150 shares, vesting in 36 equal monthly installments, and a separate nonstatutory option for 2,911 shares that vests in full on June 11, 2026, in each case conditioned on continued service. Olema highlighted his extensive business development and leadership experience across multiple biopharmaceutical companies as it advances palazestrant in two Phase 3 trials and OP-3136 in a Phase 1 study.
Olema Oncology reported fourth-quarter and full-year 2025 results, highlighting progress in its breast cancer pipeline and a stronger balance sheet. The company raised approximately $218.5 million in a follow-on offering and ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities.
Net loss widened to $46.1 million for the quarter and $162.5 million for the year, mainly from higher research and development and corporate spending as Phase 3 trials for palazestrant and a Phase 1 study for OP-3136 advanced. Non-GAAP R&D and G&A expenses also increased as Olema built late-stage and future commercial capabilities.
The company expects initial OP-3136 clinical data in Q2 2026 and top-line Phase 3 OPERA-01 results for palazestrant in the fall of 2026, while preparing for a potential first commercial launch in late 2027.
Olema Pharmaceuticals announced that Chief Operating and Financial Officer Shane Kovacs is leaving the company effective January 30, 2026, to pursue new opportunities. He will remain as a consultant through August 1, 2026, and his existing equity awards will continue to vest during this period.
Under a separation and consulting agreement, Kovacs will receive a lump-sum payment of $621,283, including $562,640 (12 months of base salary), $23,443 (pro-rated 2026 target bonus at 100% achievement), and $35,200 for COBRA health coverage gross-up. The company states his departure is not due to any disagreement over financial operations, policies, or practices. CEO Sean Bohen, M.D., Ph.D., has taken on the role of interim principal financial officer until a new Chief Financial Officer is appointed.
Olema Pharmaceuticals reported that its preliminary, unaudited cash, cash equivalents and marketable securities as of December 31, 2025 were greater than $500 million. This early estimate is based on year-end data but may change once the company completes its full financial closing procedures and audit for the 2025 fiscal year.
The company emphasized that this cash figure is preliminary, unaudited, and should not replace the detailed financial statements that will appear in its upcoming annual report on Form 10-K. Olema also posted an investor presentation on its website and furnished it as an exhibit, providing additional background for investors and other stakeholders.
Olema Pharmaceuticals, Inc. (OLMA) announced a follow-on public offering of 10,000,000 shares of common stock at $19.00 per share under an existing shelf registration. The company expects the offering to close on November 20, 2025, subject to customary conditions, and has granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price less underwriting discounts and commissions.
The transaction is expected to generate approximately $190.0 million in gross proceeds for Olema before underwriting discounts, commissions, and estimated expenses, assuming the underwriters do not exercise their option. The deal is led by TD Securities (USA) LLC as representative of the underwriters, and Olema has provided customary representations, warranties, indemnification and closing conditions as part of the underwriting agreement.
Olema Pharmaceuticals, Inc. reported that it has terminated its existing at-the-market prospectus used for sales of its common stock under a Sales Agreement with TD Securities (USA) LLC. This means the company will no longer sell shares through that at-the-market program unless and until it files a new prospectus, prospectus supplement, or registration statement. The underlying Sales Agreement itself remains in effect, so Olema could resume at-the-market sales in the future once new offering documents are in place.
Olema Pharmaceuticals (OLMA) furnished an update on its business by reporting financial results for the quarter ended September 30, 2025. The company submitted a Current Report on Form 8-K under Item 2.02 and included a press release as Exhibit 99.1. The disclosure is designated as furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liabilities and is incorporated by reference only if specifically stated.
Olema Pharmaceuticals (OLMA) reported updated Phase 1b/2 results for palazestrant combined with ribociclib in ER+/HER2- advanced or metastatic breast cancer. As of July 8, 2025, 72 patients were enrolled across 90 mg and 120 mg palazestrant dose cohorts alongside ribociclib 600 mg daily.
Efficacy in the 120 mg cohort (median follow-up >19 months) showed mature results with median progression-free survival (mPFS) of 15.5 months for all patients. Among those previously treated with CDK4/6 inhibitors, mPFS was 12.2 months, including 9.2 months for ESR1 wild-type tumors and 13.8 months for ESR1-mutant tumors. In the 90 mg cohort (median follow-up 10.8 months), mPFS was not reached.
The combination was well tolerated with no new safety signals, no observed drug–drug interactions, and mostly grade 1–2 adverse events, consistent with known profiles. These findings support the ongoing pivotal Phase 3 OPERA-02 trial of palazestrant plus ribociclib in frontline ER+/HER2- metastatic breast cancer.
Olema Pharmaceuticals, Inc. reported that it has entered into a new clinical trial collaboration and supply agreement with Pfizer Inc. to study a combination treatment for certain breast cancers. The companies plan a Phase 1b/2 study evaluating the safety and combinability of palazestrant with atirmociclib, Pfizer’s investigational, highly selective CDK4 inhibitor, in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.
Under the agreement, Pfizer will supply atirmociclib for the study, while Olema will lead the conduct of the trial. All clinical data and inventions related to the combined use of atirmociclib and palazestrant will be jointly owned, and Olema will retain full global commercial and marketing rights to palazestrant. This is the second clinical trial agreement between the two companies, following an earlier collaboration formed in November 2020.
Olema Pharmaceuticals reported its financial results for the quarter ended June 30, 2025 and furnished a press release and an investor presentation as exhibits to this Current Report. The filing identifies the press release as Exhibit 99.1, the investor presentation as Exhibit 99.2, and the cover page interactive data file as Exhibit 104. The company states these materials are being furnished and are not deemed "filed" under Section 18 of the Exchange Act.
The 8-K does not include numerical financial metrics within the text; investors seeking revenue, earnings, or other performance figures must review the attached Exhibit 99.1 press release or Exhibit 99.2 presentation or consult the company website where the presentation was made available.